ViiV Healthcare’s investigational broadly neutralising antibody – N6LS – successfully maintains viral suppression in long-acting treatment of HIV

The team at Sea­port Ther­a­peu­tics, a Boston neu­ropsy­chi­a­try biotech, is hav­ing a good fall sea­son. Sea­port said Mon­day it has pieced to­geth­er $225 mil­lion from

The phar­ma in­dus­try got a glimpse Thurs­day night of what four more years of the Biden ad­min­is­tra­tion could look like. And they did not like